Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZJXPF)

Drug Name	PMID28394193-Compound-45 Drug Info
Cross-matching ID	PubChem CID 118607675 TTD Drug ID DMZJXPF

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Patented Agent(s)

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting EZH2 Y641N mutant (EZH2 Y641N)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID28394193-Compound-56	DMQRFZK	N. A.	N. A.	Patented	[1]
PMID28394193-Compound-46	DMYMPNA	N. A.	N. A.	Patented	[1]
PMID28394193-Compound-57	DM4Y3US	N. A.	N. A.	Patented	[1]
PMID28394193-Compound-55	DM2FPHZ	N. A.	N. A.	Patented	[1]
------------------------------------------------------------------------------------

Drug(s) Targeting Enhancer of zeste homolog 2 (EZH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tazemetostat	DMWP1BH	Follicular lymphoma	2A80	Approved	[2]
DS-3201b	DMI69E5	T-cell leukaemia	2A90	Phase 2	[3]
CPI-1205	DM3XWJ8	Prostate cancer	2C82.0	Phase 1/2	[4]
SHR2554	DMMUCH0	Prostate cancer	2C82.0	Phase 1/2	[5]
CPI-0209	DMJEXLI	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[6]
DS-3201	DMRLPFG	Acute lymphoblastic leukaemia	2A85	Phase 1	[4]
HH2853	DMQIE58	Non-hodgkin lymphoma	2B33.5	Phase 1	[7]
GSK2816126	DMJDVW4	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
PF-06821497	DML3WT6	Diffuse large B-cell lymphoma	2A81	Phase 1	[9]
PMID28394193-Compound-56	DMQRFZK	N. A.	N. A.	Patented	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Enhancer of zeste homolog 2 (EZH2)	TT9MZCQ	EZH2_HUMAN	Inhibitor	[1]
EZH2 Y641N mutant (EZH2 Y641N)	TTJW2UQ	EZH2_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
3	Development of new agents for peripheral T-cell lymphoma. Expert Opin Biol Ther. 2019 Mar;19(3):197-209.
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease. Nat Rev Drug Discov. 2021 Apr;20(4):265-286.
6	ClinicalTrials.gov (NCT04104776) A Study of CPI-0209 in Patients With Advanced Tumors. U.S. National Institutes of Health.
7	Clinical pipeline report, company report or official report of HaiHe Biopharma.
8	National Cancer Institute Drug Dictionary (drug id 756211).
9	Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497). J Med Chem. 2018 Feb 8;61(3):650-665.